The Searle Company Limited
By PSX Investors Zone · Updated October 20, 2026
The Searle Company Limited (PSX: SEARL) is a Pakistani pharmaceutical company engaged in manufacturing pharmaceutical and consumer products. Incorporated in 1965, it operates in Pakistan's healthcare and medicines market. In FY2026, the company reported sales of approximately Rs. 31.64 billion, profit after tax of Rs. 4.00 billion and earnings per share of Rs. 6.81. Investors researching SEARL should assess its earnings recovery, product portfolio, margins, regulatory environment, cash flow, Shariah screening status and the Risk Warning Alert displayed on its PSX profile. Past financial performance does not guarantee future results. Sources: https://dps.psx.com.pk/company/SEARL | https://searlecompany.com/investor-information/
Company Overview
The Searle Company Limited (PSX: SEARL) is a Pakistani pharmaceutical company incorporated as a private limited company in October 1965. It was converted into a public limited company in November 1993. Its principal activities include manufacturing pharmaceutical and other consumer products.
The company's parent company is International Brands (Private) Limited, which holds a majority shareholding, as reported on the PSX company profile.
Official sources:
- PSX Company Profile — SEARL
- Searle Investor Information
- Searle Annual Reports and Financial Statements
Business Model
Searle operates in the pharmaceutical and healthcare products market. Its performance depends on product demand, manufacturing efficiency, product mix, distribution, pricing, regulatory requirements and the cost of raw materials.
Pharmaceutical businesses also face risks related to product approvals, quality standards, competition, supply chains and changes in healthcare policy. Investors should review the company's annual report for details about its product portfolio, subsidiaries, export activities and strategic priorities.
Fundamental Analysis
The following figures are from the standardized financial information displayed on the PSX company profile. Amounts are converted from thousands of Pakistani rupees into billions for readability.
| Financial Metric | FY2026 | FY2025 |
|---|---|---|
| Sales | Rs. 31.64bn | Rs. 24.77bn |
| Profit after tax | Rs. 4.00bn | Rs. 0.43bn |
| Earnings per share (EPS) | Rs. 6.81 | Rs. 0.74 |
| Gross profit margin | 52.94% | 50.81% |
| Net profit margin | 12.65% | 1.75% |
Source: PSX SEARL Financial Profile
What the numbers indicate
Searle reported higher sales and a substantial recovery in profit after tax during FY2026 compared with FY2025. Its reported gross and net profit margins also improved.
Investors should not assume that this improvement will automatically continue. Review the FY2026 annual report to understand the sources of the earnings recovery, the role of operating performance and other income or expenses, and whether cash flow supports the reported profit.
PSX notes that standardized financial data may differ from figures in the issuer's original reports. Refer to the company's annual report for detailed analysis and confirm whether each figure is standalone or consolidated.
Quarterly Performance
The PSX profile provides the following figures for the first three quarters of FY2026:
| Financial Metric | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
|---|---|---|---|
| Sales | Rs. 8.57bn | Rs. 9.02bn | Rs. 8.60bn |
| Profit after tax | Rs. 853.52m | Rs. 931.29m | Rs. 524.35m |
| EPS | Rs. 1.67 | Rs. 1.58 | Rs. 0.89 |
Source: PSX SEARL Quarterly Financials
Reported quarterly profit declined in Q3 compared with Q1 and Q2. Investors should compare the results with the corresponding prior-year quarters and examine the original quarterly statements to understand the factors behind the changes.
These quarterly figures are not a substitute for the full FY2026 annual results.
Share Price and Valuation
The PSX quote snapshot dated 19 October 2026 showed:
| Market Metric | Value |
|---|---|
| Reference share price | Rs. 76.32 |
| P/E ratio (TTM) | 11.21 |
| 52-week high | Rs. 137.44 |
| 52-week low | Rs. 75.13 |
Source: PSX SEARL Quote
These are dated market figures, not a live quote. Refresh them from PSX before publishing.
The price-to-earnings ratio compares a share's market price with its earnings per share. It should be assessed alongside earnings quality, growth prospects, cash flow, debt, business risks and the sustainability of profits. A single valuation ratio does not establish whether a share is cheap or expensive.
Dividend Information
Check the latest official PSX payout records and company announcements before publishing a dividend amount or yield. Do not assume that a return to profitability means a dividend has been declared.
Sources:
If a dividend is confirmed, state the amount, financial period, announcement date and relevant entitlement dates. Calculate yield only using a confirmed dividend and a clearly identified share-price date.
Shariah Screening Status
The PSX stock screener lists SEARL among the constituents of the KMI-30 and KMI All Share indices in the available market snapshot. This supports checking its Shariah screening status through the Exchange's official publications, but the latest applicable notice and effective date should be confirmed before publishing.
Official sources:
Shariah screening status is date- and methodology-dependent. Do not present an older index listing as a permanent guarantee of compliance. Verify the latest screening notice before describing SEARL as Shariah-compliant.
Important PSX Risk Warning Alert
The official PSX profile displays a Risk Warning Alert stating that the company is in continuous violation of specified clauses 5.11.1 or 5.11.2 and may face suspension of trading or delisting under applicable Exchange conditions.
Source: PSX SEARL Company Profile
This alert is material information and must not be omitted. Check the latest PSX notices to identify the current compliance issue and any subsequent action. The alert does not, by itself, prove that trading has already been suspended or that the company has been delisted.
Key Risks for Investors
- Regulatory risk: Pharmaceutical manufacturing and marketing are subject to regulatory and quality requirements.
- Raw-material costs: Imported ingredients and foreign-exchange movements may affect production costs.
- Earnings sustainability: The FY2026 profit recovery should be examined against operating cash flow and the original annual report.
- Competition: Other pharmaceutical manufacturers compete on product availability, pricing and distribution.
- Product and supply risks: Quality, manufacturing, distribution and supply-chain disruptions may affect performance.
- PSX compliance risk: The current Risk Warning Alert requires careful review.
- Shariah screening changes: Confirm the latest official screening status before relying on it.
Investor Research Checklist
Before assessing SEARL, review:
- The FY2026 annual report and latest quarterly statements.
- Sales, EPS, gross margin and net margin trends.
- Operating cash flow, borrowings and finance costs.
- The sources of the FY2026 earnings recovery.
- Current market price, valuation and confirmed dividend announcements.
- The latest official Shariah screening notice.
- Current PSX notices relating to the Risk Warning Alert.
Frequently Asked Questions
What is the PSX symbol for The Searle Company Limited?
Its Pakistan Stock Exchange symbol is SEARL.
What does Searle Company do?
It manufactures pharmaceutical and other consumer products.
Was SEARL listed in Shariah-related PSX indices?
The available PSX screener snapshot lists SEARL in KMI-30 and KMI All Share constituents. Confirm the latest official screening notice and effective date before relying on this status.
What is an important caution for SEARL investors?
The PSX profile displays a Risk Warning Alert. Investors should review the underlying compliance issue alongside the company's annual report, cash flow and current regulatory disclosures.
Disclaimer
This profile is for educational and informational purposes only and is not a recommendation to buy or sell SEARL shares. Financial results, market prices, regulatory notices and Shariah screening status can change. Verify the latest official information before making investment decisions.
This profile is for educational purposes and is not a recommendation to buy or sell any security.